Novartis (NYSE:NVS) is a global healthcare company based in Switzerland, known for its innovative medicines and treatments. It operates in various segments, including pharmaceuticals and generics. Novartis competes with other major pharmaceutical companies like Pfizer and Roche. On October 29, 2025, Wan Nurhayati from CFRA set a price target of $126 for NVS, which was trading at $123.33 at the time.
This price target suggests a potential increase of about 2.16%. Zacks Investment Research highlights Novartis as a top value stock for long-term investment. They emphasize the importance of selecting strong, market-beating stocks for an investment portfolio, and Novartis fits this criterion. The Zacks Rank and Zacks Industry Rank are tools that help investors make informed decisions.
Zacks Style Scores rate stocks based on value, growth, and momentum, identifying those with the best potential to outperform the market in the short term. Novartis is suggested to have a favorable rating, making it a compelling choice for investors seeking value stocks. The current stock price of NVS is $123.12, reflecting a decrease of 0.31, or -0.25%.
Today, the stock has traded between $121.65 and $123.91. Over the past year, NVS has reached a high of $133.55 and a low of $96.06. With a market capitalization of approximately $240.22 billion, Novartis remains a significant player in the pharmaceutical industry. The trading volume for the day is 1,552,411 shares on the NYSE.
